TY - JOUR
T1 - Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma
AU - the Study Group for Vitreoretinal Lymphoma Diagnostics
AU - Carbonell, Denise
AU - Mahajan, Sarakshi
AU - Chee, Soon Phaik
AU - Sobolewska, Bianka
AU - Agrawal, Rupesh
AU - Bülow, Tanja
AU - Gupta, Vishali
AU - Jones, Nicholas P.
AU - Accorinti, Massimo
AU - Agarwal, Mamta
AU - Batchelor, Tracy
AU - Biswas, Jyotirmay
AU - Cimino, Luca
AU - tenDam-van Loon, Ninette H.
AU - de-la-Torre, Alejandra
AU - Frenkel, Shahar
AU - Pe’er, Jacob
AU - Kramer, Michal
AU - Miserocchi, Elisabetta
AU - Mochizuki, Manabu
AU - Ness, Thomas
AU - Rosenbaum, James T.
AU - Sen, H. Nida
AU - Simion, Michael
AU - Sitter, Helmut
AU - Vasconcelos-Santos, Daniel V.
AU - Habot-Wilner, Zohar
AU - Coupland, Sarah E.
AU - Pulido, José S.
AU - Smith, Justine
AU - Thorne, Jennifer E.
AU - Zierhut, Manfred
N1 - Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - Purpose: To provide recommendations for diagnosis of vitreoretinal lymphoma (VRL). Methods: Literature was reviewed for reports supporting the diagnosis of VRL. A questionnaire (Delphi 1 round) was distributed to 28 participants. In the second round (Delphi 2), items of the questionnaire not reaching consensus (75% agreement) were discussed to finalize the recommendations. Results: Presenting symptoms include floaters and painless loss of vision, vitreous cells organized into sheets or clumps. Retinal lesions are usually multifocal creamy/white in the outer retina. Other findings include retinal lesions with “leopard-skin” appearance and retinal pigment epithelium atrophy. Severe vitreous infiltration without macular edema is the most likely presentation. Diagnostic vitrectomy should be performed. Systemic corticosteroid should be discontinued at least 2 weeks before surgery. An interleukin (IL)-10:IL-6 ratio > 1, positive mutation for the myeloid differentiation primary response 88 gene and monoclonality are indicators of VRL. Multi-modal imaging (optical coherence tomography, fundus autofluorescence) are recommended. Conclusions: A consensus meeting allowed the establishment of recommendations important for the diagnosis of VRL.
AB - Purpose: To provide recommendations for diagnosis of vitreoretinal lymphoma (VRL). Methods: Literature was reviewed for reports supporting the diagnosis of VRL. A questionnaire (Delphi 1 round) was distributed to 28 participants. In the second round (Delphi 2), items of the questionnaire not reaching consensus (75% agreement) were discussed to finalize the recommendations. Results: Presenting symptoms include floaters and painless loss of vision, vitreous cells organized into sheets or clumps. Retinal lesions are usually multifocal creamy/white in the outer retina. Other findings include retinal lesions with “leopard-skin” appearance and retinal pigment epithelium atrophy. Severe vitreous infiltration without macular edema is the most likely presentation. Diagnostic vitrectomy should be performed. Systemic corticosteroid should be discontinued at least 2 weeks before surgery. An interleukin (IL)-10:IL-6 ratio > 1, positive mutation for the myeloid differentiation primary response 88 gene and monoclonality are indicators of VRL. Multi-modal imaging (optical coherence tomography, fundus autofluorescence) are recommended. Conclusions: A consensus meeting allowed the establishment of recommendations important for the diagnosis of VRL.
KW - Vitreoretinal lymphoma
KW - consensus recommendations
KW - diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85111001721&partnerID=8YFLogxK
U2 - 10.1080/09273948.2021.1878233
DO - 10.1080/09273948.2021.1878233
M3 - Article
C2 - 34009095
AN - SCOPUS:85111001721
SN - 0927-3948
VL - 29
SP - 507
EP - 520
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 3
ER -